» Articles » PMID: 21751270

Vessel Size Index Measurements in a Rat Model of Glioma: Comparison of the Dynamic (Gd) and Steady-state (iron-oxide) Susceptibility Contrast MRI Approaches

Overview
Journal NMR Biomed
Publisher Wiley
Date 2011 Jul 14
PMID 21751270
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Vessel size index (VSI), a parameter related to the distribution of vessel diameters, may be estimated using two MRI approaches: (i) dynamic susceptibility contrast (DSC) MRI following the injection of a bolus of Gd-chelate. This technique is routinely applied in the clinic to assess intracranial tissue perfusion in patients; (ii) steady-state susceptibility contrast with USPIO contrast agents, which is considered here as the standard method. Such agents are not available for human yet and the steady-state approach is currently limited to animal studies. The aim is to compare VSI estimates obtained with these two approaches on rats bearing C6 glioma (n = 7). In a first session, VSI was estimated from two consecutive injections of Gd-Chelate (Gd(1) and Gd(2)). In a second session (4 hours later), VSI was estimated using USPIO. Our findings indicate that both approaches yield comparable VSI estimates both in contralateral (VSI{USPIO} = 7.5 ± 2.0 µm, VSI{Gd(1)} = 6.5 ± 0.7 µm) and in brain tumour tissues (VSI{USPIO} = 19.4 ± 7.1 µm, VSI{Gd(1)} = 16.6 ± 4.5 µm). We also observed that, in the presence of BBB leakage (as it occurs typically in brain tumours), applying a preload of Gd-chelate improves the VSI estimate with the DSC approach both in contralateral (VSI{Gd(2)} = 7.1 ± 0.4 µm) and in brain tumour tissues (VSI{Gd(2)} = 18.5 ± 4.3 µm) but is not mandatory. VSI estimates do not appear to be sensitive to T(1) changes related to Gd extravasation. These results suggest that robust VSI estimates may be obtained in patients at 3 T or higher magnetic fields with the DSC approach.

Citing Articles

Aberrant vascular architecture in the hippocampus correlates with tau burden in mild cognitive impairment and Alzheimer's disease.

Lee H, Fu J, Gaudet K, Bryant A, Price J, Bennett R J Cereb Blood Flow Metab. 2023; 44(5):787-800.

PMID: 38000018 PMC: 11197134. DOI: 10.1177/0271678X231216144.


Evaluation of contrast agent dose and diffusion coefficient measurement on vessel size index estimation.

Vejdani Afkham B, Masjoodi S, Oghabian M, Ghodsi S, Nazem Zadeh M, Esmati E MAGMA. 2019; 32(5):529-537.

PMID: 31270714 DOI: 10.1007/s10334-019-00760-4.


Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging.

Boult J, Borri M, Jury A, Popov S, Box G, Perryman L NMR Biomed. 2016; 29(11):1608-1617.

PMID: 27671990 PMC: 5082561. DOI: 10.1002/nbm.3594.


Assessment of a simplified spin and gradient echo (sSAGE) approach for human brain tumor perfusion imaging.

Stokes A, Skinner J, Yankeelov T, Quarles C Magn Reson Imaging. 2016; 34(9):1248-1255.

PMID: 27457801 PMC: 5055446. DOI: 10.1016/j.mri.2016.07.004.


Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.

OHalloran P, Viel T, Murray D, Wachsmuth L, Schwegmann K, Wagner S Eur J Nucl Med Mol Imaging. 2016; 43(9):1673-83.

PMID: 26975402 DOI: 10.1007/s00259-016-3343-3.